Review But many critics are urging still other changes, including easier approval of 'off-label' uses
DÉJÀ VU: NCI's David Parkinson sees parallels with AIDS drug testing.
Proponents of the changes contend they will expedite patients' access to potentially life-saving medications.
STEPPING UP: Jefferson University's Robert Comis supports reform.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!